About
Neurozen is dedicated to developing advanced, deep learning-enabled neuroimaging and genetic solutions for the risk assessment and early detection of Alzheimer's disease. Risk assessment and early detection are crucial to helping target the disease before irreversible brain damage or mental decline has occurred. Our mission is to provide innovative, quality clinical tools to predict, quantify, and monitor neurodegeneration as well as so that physicians can be more confident in making important clinical decisions and people can enjoy a higher quality of life.
Technologies
Apache
WordPress.org
Mobile Friendly
AI
Keywords
genetic analysis
neuroimaging
alzheimers disease
medical device
kcdc genetic test
apoe genotype prediction
risk prediction models
healthcare
deep learning
neuroinformatics network
risk assessment
neuropsychological testing
neurodegeneration quantification
mri
genomics
biomarker prediction
genomics-based prediction
radiology
clinical trial tools
early detection
b2b
alzheimers prediction
kfda medical device
longitudinal cohort
multimodal data
neuroinformatics
gard cohort
services
clinical decision support
quantitative brain imaging
Company Information
-
Employees 7
-
Founded 2015
Location
Seoul, South Korea
